BACKGROUND/AIMS: The role of liver resection for hepatic metastases from noncolorectal carcinomas has yet to be clarified. The present study examines a single institutional experience of hepatic resection for noncolorectal metastases. METHODOLOGY: From January 1987 to March 1999, 14 patients underwent curative resection for liver metastases from noncolorectal carcinomas. Records of these patients were reviewed. RESULTS: Resections were performed for liver metastases from gastric cancers (n = 8), pancreatic cancers (n = 2), and cancers of bile duct, the papilla of Vater, kidney, and breast (n = 1, each). Six patients (5 with gastric cancers and 1 with pancreas cancer) presented with synchronous disease and 8 with metachronous disease. In the gastric cancer patients, there are 2 disease-free survivors (26 and 53 months) in the metachronous group, though all of the 5 patients with synchronous disease died within 29 months. All of the 4 patients with pancreatobiliary carcinomas died within 2 years. One case of breast cancer and another of renal cell cancer are alive without disease at 49 and 9 months, respectively. CONCLUSIONS: For metastases from gastric cancers, better survival after hepatic resection is expected in metachronous cases than in synchronous cases. Hepatic resection may afford little benefit for patients with liver metastases from pancretobiliary cancers.
BACKGROUND/AIMS: The role of liver resection for hepatic metastases from noncolorectal carcinomas has yet to be clarified. The present study examines a single institutional experience of hepatic resection for noncolorectal metastases. METHODOLOGY: From January 1987 to March 1999, 14 patients underwent curative resection for liver metastases from noncolorectal carcinomas. Records of these patients were reviewed. RESULTS: Resections were performed for liver metastases from gastric cancers (n = 8), pancreatic cancers (n = 2), and cancers of bile duct, the papilla of Vater, kidney, and breast (n = 1, each). Six patients (5 with gastric cancers and 1 with pancreas cancer) presented with synchronous disease and 8 with metachronous disease. In the gastric cancerpatients, there are 2 disease-free survivors (26 and 53 months) in the metachronous group, though all of the 5 patients with synchronous disease died within 29 months. All of the 4 patients with pancreatobiliary carcinomas died within 2 years. One case of breast cancer and another of renal cell cancer are alive without disease at 49 and 9 months, respectively. CONCLUSIONS: For metastases from gastric cancers, better survival after hepatic resection is expected in metachronous cases than in synchronous cases. Hepatic resection may afford little benefit for patients with liver metastases from pancretobiliary cancers.
Authors: Tobias S Schiergens; Juliane Lüning; Bernhard W Renz; Michael Thomas; Sebastian Pratschke; Hao Feng; Serene M L Lee; Jutta Engel; Markus Rentsch; Markus Guba; Jens Werner; Wolfgang E Thasler Journal: J Gastrointest Surg Date: 2016-02-26 Impact factor: 3.452
Authors: Jürgen Weitz; Leslie H Blumgart; Yuman Fong; William R Jarnagin; Michael D'Angelica; Lawrence E Harrison; Ronald P DeMatteo Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: René Adam; Laurence Chiche; Thomas Aloia; Dominique Elias; Rémy Salmon; Michel Rivoire; Daniel Jaeck; Jean Saric; Yves Patrice Le Treut; Jacques Belghiti; Georges Mantion; Gilles Mentha Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: J Lendoire; M Moro; O Andriani; J Grondona; O Gil; G Raffin; J Silva; R Bracco; G Podestá; C Valenzuela; O Imventarza; J Pekolj; E De Santibañes Journal: HPB (Oxford) Date: 2007 Impact factor: 3.647
Authors: Emmanuel Buc; David Orry; Olivier Antomarchi; Johan Gagnière; David Da Ines; Denis Pezet Journal: World J Surg Oncol Date: 2014-11-18 Impact factor: 2.754